(Q34038277)

English

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

J C von Einem

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

V Heinemann

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

L Fischer von Weikersthal

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

U Vehling-Kaiser

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Stauch

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

H G Hass

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

T Decker

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Klein

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Held

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Jung

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

T Kirchner

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Haas

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Holch

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Michl

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

P Aubele

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Boeck

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Schulz

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Giessen

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Stintzing

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D P Modest

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

10 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

140

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1607-1614

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

10 May 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Colorectal cancer: a tale of two sides or a continuum?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

5 July 2018

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1678-3

21 January 2018

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1678-3

21 January 2018

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1678-3

21 January 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4131148

29 October 2018

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24816724

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/24816724

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-014-1678-3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34038277&oldid=2196156677"